For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| General and administrative | - | - | - | 5,154* |
| Total revenues | 0 | 0 | - | 369 |
| Acquired in-process research and development | 45,000 | 0 | - | -42,001* |
| Research and development | 35,529 | 24,817 | 24,600 | 43,250* |
| General and administrative | 8,099 | 6,502 | 6,179 | - |
| Reversal due to settlement of indirect tax liabilities | 0 | -3,935 | -5,510 | - |
| Total operating expenses | 88,628 | 27,384 | 25,269 | 6,403 |
| Loss from operations | -88,628 | -27,384 | -25,269 | -6,034* |
| Other expense, net | 0 | 0 | 110 | - |
| Interest income, net | 5,395 | 1,666 | 1,899 | 362 |
| Total other income, net | 5,395 | 1,666 | 1,789 | 362* |
| Net loss from continuing operations before income tax expense | - | - | - | -5,673 |
| Net loss from continuing operations | -83,233 | -25,718 | -23,480 | -5,673* |
| (gain) income from discontinued operations (including gain on disposal of discontinued operations of zero and 1,799 during the three and nine months ended september 30, 2024, respectively), net of income taxes | 0 | 0 | - | -3,362* |
| Net loss | -83,233 | -25,718 | -23,480 | -9,036 |
| Unrealized loss on available-for-sale investments | -107 | - | - | - |
| Comprehensive loss | -83,340 | - | - | - |
| Basic EPS | -3.1 | -1.65 | -1.66 | -1.136 |
| Diluted EPS | -3.1 | -1.65 | -1.66 | -1.136 |
| Basic Average Shares | 26,882,366 | 15,547,403 | 14,177,743 | 7,955,010 |
| Diluted Average Shares | 26,882,366 | 15,547,403 | 14,177,743 | 7,955,010 |
Cidara Therapeutics, Inc. (CDTX)
Cidara Therapeutics, Inc. (CDTX)